Lung Cancer News and Research

Latest Lung Cancer News and Research

Cancer-related fatigue linked to muscle mass and strength

Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.

10 Feb 2012

Two new cancer research laboratories at WEHI receive $2M ACRF funding

The Australian Cancer Research Foundation (ACRF) has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute.

9 Feb 2012

Link between coronary artery disease and prostate cancer

In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.

8 Feb 2012

Soy isoflavone supplements do not reduce breast cancer cell proliferation

Soy isoflavone supplements did not decrease breast cancer cell proliferation in a randomized clinical trial, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Feb 2012

Molecular subtypes of lung cancer manifest as different diseases

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.

3 Feb 2012

Patients' financial health put at risk by costs of some medical treatments

A New Jersey newspaper explores how medical costs put patients at financial risk. Also, the NewsHour explores the future of health care, offering alternative scenarios about how policy decisions, political outcomes and technology might play into an individual's health.

2 Feb 2012

Healthy lung tissue transplantation shows promise for patients with pulmonary diseases

For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.

2 Feb 2012

BU scientists create unique material and drug delivery mechanism

Long duration, controllable drug delivery is of wide interest to medical researchers and clinicians, particularly those seeking to improve treatment for patients with chronic pain or to prevent cancer recurrence after surgery. Now a team of researchers led by Boston University Biomedical Engineer and Chemist Mark Grinstaff has developed a unique material and drug delivery mechanism that could pave the way for implants that release a drug at a designated rate for months.

1 Feb 2012

Crizotinib can treat ROS1-driven tumors

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S.

1 Feb 2012

Array second quarter revenue increases to $23.2 million

Array BioPharma Inc. today reported financial results for the second quarter of fiscal 2012.

31 Jan 2012

FDA approves Medtronic DF4 High-Voltage Connector System for ICDs and CRT-Ds

Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.

From Medtronic 30 Jan 2012

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian Technologies Limited announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection.

30 Jan 2012

New mechanism of drug release using 3D superhydrophobic materials

According to a recent study, there is a new mechanism of drug release using 3D superhydrophobic materials that utilizes air as a removable barrier to control the rate at which drug is released.

30 Jan 2012

Pinpoint Genomics makes Pinpoint Dx Lung Assay available to clinicians, patients

Pinpoint Genomics, Inc. announced the publication of key data relating to its Pinpoint Dx Lung Assay in the journal The Lancet, and the availability of its Pinpoint Dx Lung Assay to clinicians and patients exclusively through the company's laboratory in Mountain View, CA.

30 Jan 2012

HHMI honors EMBL Monterotondo researcher with International Early Career Scientist award

Rocio Sotillo, a staff scientist at the European Molecular Biology Laboratory (EMBL) in Monterotondo, is one of 28 outstanding young biomedical scientists who have been honoured with a Howard Hughes Medical Institute (HHMI) International Early Career Scientist award this year.

25 Jan 2012

Elevated blood lead levels put smokers at higher risk for renal cell carcinoma

Higher than normal levels of lead in the blood may signal a risk two times higher than average of developing renal cell carcinoma in smokers, according to medical researchers.

24 Jan 2012

Study provides valuable information on which cancer patients might need help to quit smoking

A new analysis has found that a substantial number of lung and colorectal cancer patients continue to smoke after being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study provides valuable information on which cancer patients might need help to quit smoking.

23 Jan 2012

Combination of gefitinib and miRNA-inhibitor might effectively treat NSCLC

New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.

20 Jan 2012

Study examines drug resistance in ALK positive lung cancer

Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer. It's the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib.

19 Jan 2012

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.

19 Jan 2012